ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,117Medicare Part D Prescriptions Filled, Including Refills

Rank: 44 out of 403

$470K Total Retail Price of All Prescriptions

Rank: 57 out of 403

291 Patients Receiving at Least One Drug in Part D
74%Patients 65 Years and Older
67% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

13% of this provider’s 291 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

9% of this provider’s 291 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

0% of this provider’s 5,330 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$66 was the average price of a prescription from this provider, compared to $72 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
LISINOPRIL 309 262 1 1
FUROSEMIDE 298 258 2 7
LEVOTHYROXINE SODIUM 270 186 3 3
SIMVASTATIN 234 207 4 2
OMEPRAZOLE 178 139 5 9
WARFARIN SODIUM 178 147 5 12
AMLODIPINE BESYLATE 177 138 7 4
METFORMIN HCL 165 116 8 8
ATORVASTATIN CALCIUM 165 128 8 5
HYDROCHLOROTHIAZIDE 151 140 10 6
METOPROLOL TARTRATE 149 128 11 10
HYDROCODONE-ACETAMINOPHEN 133 99 S3 12 15
ZOLPIDEM TARTRATE 131 84 13 16
METOPROLOL SUCCINATE 103 82 14 11
ATENOLOL 102 83 15 13
NEXIUM 94 38 16 18
TRAZODONE HCL 93 67 17 25
CITALOPRAM HBR 91 66 18 22
LANTUS 88 62 19 54
ADVAIR DISKUS 79 71 20 33
GABAPENTIN 78 51 21 17
ESCITALOPRAM OXALATE 77 73 22 36
MIRTAZAPINE 73 62 23 38
DONEPEZIL HCL 69 69 24 23
PROAIR HFA 66 34 25 40
LOSARTAN POTASSIUM 65 65 26 21
DILTIAZEM 24HR CD 61 48 27 102
FLUOXETINE HCL 60 52 28 57
LOVASTATIN 59 42 29 42
SERTRALINE HCL 58 49 30 20
JANUVIA 58 45 30 44
DIOVAN 57 40 32 24
QUETIAPINE FUMARATE 51 35 33 52
GLIPIZIDE 51 51 33 70
CELEBREX 51 37 33 87
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 24, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.